Neurocrine Likely To Seek Women’s Health Partner For Endometriosis Drug
This article was originally published in The Pink Sheet Daily
Neurocrine expects to carry development of its gonadotrophin-releasing hormone receptor antagonist through Phase IIb before partnering.
You may also be interested in...
Pfizer/Neurocrine's insomnia drug – which just had its user fee date extended – would still have class warnings, but could enjoy a labeling advantage over competitors.
Janssen's net drug prices declined for the fourth year in a row in 2020, while list prices increased 3.8%, according to the company's drug pricing report.
The company is requesting FDA expand the antibody cocktail to include a COVID prevention claim with a lower 1,200mg dose and a subcutaneously administered formula.